Navigation Links
Data in NEJM shows Novartis drug Signifor® is first therapy to provide rapid, durable benefit for Cushing's disease patients in Phase III study
Date:3/7/2012

e of approximately 50% by month two, and remained stable in both groups through the end of the study. On average, as UFC levels were reduced, clinical manifestations of Cushing's disease improved including reduction of blood pressure, total cholesterol, weight and body mass index(1).

The most frequently reported adverse events (AE) (>10%) by investigators for pasireotide were diarrhea, nausea, hyperglycemia, cholelithiasis, abdominal pain, diabetes mellitus, injection site reactions, fatigue and increased glycosylated hemoglobin (HbA1c), with most events being Grade 1-2. The tolerability profile of pasireotide was similar to that of other somatostatin analogs with the exception of the greater degree of hyperglycemia.

The trial, which represents the largest randomized study to evaluate a medical therapy in patients with Cushing's disease, is the basis for regulatory submissions for pasireotide under way worldwide for the treatment of this condition. If approved, the brand name for pasireotide will be Signifor.

"These study results demonstrate that pasireotide has the potential to be an important therapeutic option for patients living with Cushing's disease and reinforces Novartis' commitment to develop therapies to help address unmet medical needs," said Herve Hoppenot, President, Novartis Oncology. "We look forward to working with regulatory authorities worldwide to help bring this novel treatment option to market."

About the Study

PASPORT-CUSHINGS (PASireotide clinical trial PORTfolio - CUSHING'S disease) is a prospective randomized, double-blind, Phase III study conducted at 68 sites in 18 countries. The study evaluated the efficacy and safety of pasireotide in 162 adult patients with persistent or recurrent Cushing's disease and UFC levels greater than 1.5 times the upper limit of normal (ULN), as well as in patients with newly diagnosed Cushing's disease who are not candidates for surgery(1).


'/>"/>
SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
6. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
7. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
8. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
9. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
10. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
11. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014 , ... a hub of information concerning the biopharmaceutical Group,s national and ... further addition to the recently launched institutional website that is ... been enriched by a new chapter in the fascinating story ... richly detailed and panoramic hub on the world of clinical ...
(Date:12/17/2014)... 17, 2014  IGI Laboratories, Inc. (NYSE MKT: IG; ... its offering of $125 million aggregate principal amount of ... Notes were offered and sold only to qualified institutional ... of 1933, as amended (the "Securities Act"). ... 3.75% per year, payable semiannually in arrears on June ...
(Date:12/17/2014)... and RALEIGH, N.C. , ... Communications, LLC (CTMC), and Integrated Clinical Trial Services, ... and retention for clinical trials announce that they ... Trial Marketing Services (i-CTMS). i-CTMS will provide a ... to pharmaceutical, biotechnology and medical device companies. ...
Breaking Medicine Technology:Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3
... PARSIPPANY, N.J., Nov. 30, 2011  Watson Pharmaceuticals, Inc. (NYSE: ... Inc., has launched an authorized generic version of LIPITOR® ... exclusive agreement with Pfizer Inc.  Watson began shipping the ... adjunct to diet to reduce elevated total cholesterol, LDL, ...
... 2011  Vantage Health (OTC:BB – ticker symbol VNTH), ("Company"), ... Health Tanzania Limited ("VHTL"), was awarded Lot 1, Lot ... es Salaam ("University") pharmaceutical and medical supply tender number ... value for lot 1, lot 2 and lot 3 ...
Cached Medicine Technology:Watson Launches Generic LIPITOR® 2Watson Launches Generic LIPITOR® 3Vantage Health 51% Owned Tanzanian Subsidiary Awarded Lot 1, Lot 2 and Lot 3 of University of Dar Es Salaam Pharmaceutical and Medical Supply Tender 2Vantage Health 51% Owned Tanzanian Subsidiary Awarded Lot 1, Lot 2 and Lot 3 of University of Dar Es Salaam Pharmaceutical and Medical Supply Tender 3
(Date:12/19/2014)... Santa Rosa, CA (PRWEB) December 19, 2014 ... 2x4 and 5x5 SuperClone Rooms. SuperCloset continues to offer ... grow solutions. Pair one of the new SuperClone Rooms ... truly professional, perpetual, and turnkey indoor hydroponic grow room ... cloner in the world, SuperCloset’s SuperPonic SuperCloner 50 ...
(Date:12/19/2014)... The Medspa at Hendrick in Abilene, TX presents ... brand Juvéderm. Voluma XC treats volume loss in cheeks, ... Hendrick is pleased to be able to offer this ... clients. , Voluma is the first and only injectable ... mid-face and cheek area. This non-invasive treatment targets volume ...
(Date:12/19/2014)... FRIDAY, Dec. 19, 2014 (HealthDay News) -- All children ... 3 and 6, preferably every year, eye experts say. ... from an expert panel of the U.S. National Center ... children in this age group require screening for eye ... glasses, such as amblyopia ("lazy eye") and strabismus (a ...
(Date:12/19/2014)... Dec. 19, 2014 (HealthDay News) -- The cost of ... well-being, a new study finds. Researchers examined data ... been diagnosed with colorectal or lung cancer. Of those ... cancer-free, and more than 100 had advanced cancer. ... to pay their medical bills, which was linked with ...
(Date:12/19/2014)... Dennis Thompson HealthDay Reporter ... Ebola,s entrance into the United States -- along with ... outbreak -- have highlighted cracks in the nation,s public ... health policy report released Thursday. Half of U.S. ... to infectious disease outbreaks. That was the main conclusion ...
Breaking Medicine News(10 mins):Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2Health News:Preschoolers Need Eye Screening, Experts Say 2Health News:Cancer Treatment Costs Weigh Heavily on Patients, Study Finds 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 3Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 4
... Blue companies, stewardship of,healthcare dollars, WASHINGTON, June ... investigations resulted in overall savings and,recoveries of more ... released,by the Blue Cross and Blue Shield Association ... Blue Cross and Blue Shield companies, anti-fraud,units was ...
... HARRISBURG, Pa., June 19 Four illnesses,caused ... State Health Secretary Dr. Calvin B. Johnson announced ... Salmonella outbreak,associated with tomatoes that has produced at ... has been identified in Bucks, Butler, Lancaster, and,Warren ...
... year, the ESMO International Symposium: 10th World ... from 6 leading professional societies and organizations, ... the premier platform for specialists in cancer ... review the state-of-the-art in gastrointestinal cancer and ...
... the Necessity of ... Healthcare ... to gauge,healthcare professionals, attitudes about universal coverage and the,candidates, programs, ... the U.S. A nationwide,representative sample of 336 general practitioners, internal ...
... - Adds $47 million in annual revenues and eight locations in ... Connecticut, ... Inc.,(Nasdaq: AFAM ), a leading regional provider of home health ... the stock of Patient Care, Inc. This acquisition, the Company,s,largest to ...
... Schmidt teams up with Minor League Baseball(TM) to raise awareness of, ... ... in the U.S., BRIDGEWATER, N.J., June 19 Hall of Fame ... teamed up to launch BPH Game Plan Starts with U:,Catch the Whole ...
Cached Medicine News:Health News:Blue Cross and Blue Shield Companies' Anti-Fraud Units Recover and Save More Than $249 Million In 2007 2Health News:Blue Cross and Blue Shield Companies' Anti-Fraud Units Recover and Save More Than $249 Million In 2007 3Health News:Pennsylvania Department of Health Investigates Salmonella Cases Linked to National Outbreak 2Health News:10th World Congress on Gastrointestinal Cancer -- Barcelona, Spain 2Health News:U.S. Healthcare Professionals Speak Out on Universal Healthcare and the Presidential Candidates' Platforms 2Health News:U.S. Healthcare Professionals Speak Out on Universal Healthcare and the Presidential Candidates' Platforms 3Health News:U.S. Healthcare Professionals Speak Out on Universal Healthcare and the Presidential Candidates' Platforms 4Health News:U.S. Healthcare Professionals Speak Out on Universal Healthcare and the Presidential Candidates' Platforms 5Health News:Almost Family, Inc. Signs Definitive Agreement to Acquire Patient Care, Inc. 2Health News:Almost Family, Inc. Signs Definitive Agreement to Acquire Patient Care, Inc. 3Health News:Almost Family, Inc. Signs Definitive Agreement to Acquire Patient Care, Inc. 4Health News:Hall of Fame Baseball Legend Mike Schmidt Speaks Out for the First Time About Common Health Problem in Older Men 2Health News:Hall of Fame Baseball Legend Mike Schmidt Speaks Out for the First Time About Common Health Problem in Older Men 3Health News:Hall of Fame Baseball Legend Mike Schmidt Speaks Out for the First Time About Common Health Problem in Older Men 4Health News:Hall of Fame Baseball Legend Mike Schmidt Speaks Out for the First Time About Common Health Problem in Older Men 5
Provides access via PDA to determine whether imaging examinations are necessary based on symptons and which studies will generate the most information....
PDA-version of the standard reference work in rheumatology....
PDA version of the best-selling guide....
More than 200 key diagnostic and treatment tables culled from Tierney's Current Medical Diagnostics and Treatment 2003....
Medicine Products: